Navigation Links
Motion Filed to Consolidate Yasmin/YAZ Litigation in Toledo, Ohio
Date:7/24/2009

LANCASTER, Pa., July 24 /PRNewswire-USNewswire/ -- Three leading law firms representing 23 of the 32 filed cases around the country have filed a joint motion asking that the Yasmin/YAZ product liability litigation be consolidated and transferred to Chief Judge James G. Carr of the United States District Court for the Northern District of Ohio. The motion was filed today, July 24, 2009, before the Judicial Panel on Multidistrict Litigation in Washington, D.C.

The three law firms represent Plaintiffs from across the country who have suffered injuries, including deep vein thrombosis, pulmonary embolism, heart attack, stroke, kidney failure, seizures, gall bladder injuries, and death after using the birth control pills Yasmin/YAZ and Ocella. The three firms and their lead lawyers handling this litigation are Dianne Nast and Daniel Gallucci of RodaNast, Lancaster, Pennsylvania; Janet Abaray and Michael Burg of Burg Simpson Eldredge Hersh & Jardine, Cincinnati, Ohio and Englewood, Colorado; and David Zoll, Michelle Kranz and Pamela Borgess, Zoll Kranz & Borgess, Toledo, Ohio.

The Defendants in the cases are Bayer Pharmaceuticals Corporation and other Bayer related companies. The FDA issued warning letters to Berlex Laboratories, the predecessor manufacturer to Bayer, in 2003, ordering the Defendants to immediately discontinue a television advertisement that promoted Yasmin's fourth generatio progestin, drospirenone, by stating, "Ask about Yasmin, and the difference a little chemistry can make." The FDA objected and stated "FDA is not aware of substantial evidence or clinical experience demonstrating that Yasmin is superior to other COC's [combination oral contraceptives] or that the drospirenone in Yasmin is clinically beneficial. On the contrary, FDA is aware of the added clinical risks associated with drospirenone."

The FDA issued a second warning letter to Bayer on October 3, 2008, for another advertisement, this time concerning YAZ. The FDA determined that the advertisement was misleading because it failed to disclose that "YAZ has additional risks because it contains the progestin, drospirenone . . ."

Copies of the papers and other information are available as follows:

Janet G. Abaray (513) 852-5600 jabaray@burgsimpson.com

Daniel N. Gallucci (717) 892-3000 dgallucci@rodanast.com

David W. Zoll (419) 841-9623 david@toledolaw.com


'/>"/>
SOURCE RodaNast, P.C.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. HealthFitness Helps Herbalife Engage Employees in Wellness Promotion Program Through Strategic Use of Incentives
2. Avidas(TM) Pharmaceuticals and LaRon(TM) Pharma Inc. Announce Co-Promotion Agreement
3. New Survey Highlights Emotional, Financial Toll Multi-Generational Tobacco Use Takes on Parents Sandwiched In Between
4. Savoring Happy Moments Helps Build Emotional Strength
5. Motion analysis helps soccer players get their kicks
6. CyberGlove Systems Hosts Worldwide Contest for New Motion Capture Technology Applications
7. NetMotion Wireless Enhances Mobile Productivity and Security at Wichita Clinic
8. Lifeclinic Supports Healthy Workforce and Health Promotion First Acts
9. Lifeclinic Supports Healthy Workforce and Health Promotion First Acts
10. Delaware Chancery Court Grants Galil Medical Ltd.s Motion for Expedited Proceeding in Suit Against Endocare
11. Naps with rapid eye movement sleep increase receptiveness to positive emotion
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... ... May 27, 2016 , ... Aimed at nurses and employees in ... come courtesy of leaders in the nursing and health care industry. It also provides ... associations—namely Abilene Christian University. , As the nursing industry is coming out of ...
(Date:5/26/2016)... ... ... Despite last week’s media reports hinting at a June rate hike after the Federal ... an interest rate increase, according to Rajeev Dhawan of the Economic Forecasting Center at ... Committee (FOMC) dot charts are of interest to the press for their noise potential,” ...
(Date:5/26/2016)... California (PRWEB) , ... May 26, 2016 , ... ... associated with discovery of thousands of defective respirators, according to court documents and ... the case of William and Becky Tyler v. American Optical Corporation, Case No. ...
(Date:5/26/2016)... ... May 26, 2016 , ... Connor Sports, through ... a partner for the Tamika Catchings Legacy Tour that will commemorate the ... in hardwood basketball surfaces in all forms and levels of the game, Connor Sports ...
(Date:5/26/2016)... PA (PRWEB) , ... May 26, 2016 , ... ... and one that has a significant negative impact on long-term patient survival, reports ... date. The results, published online this week in the Journal of Thoracic and ...
Breaking Medicine News(10 mins):
(Date:5/27/2016)... Israel , May 27, 2016 ... an innovative biopharmaceutical company focused on late-stage drug ... Dexcel Pharma of pivotal batches required ... and Drug Administration (FDA). This follows Kitov,s ... Phase III trial successfully met its primary efficacy ...
(Date:5/26/2016)... -- A key trend that will boost ... new treatments. Cardax, a development stage life sciences company, ... is expected to fulfil large unmet medical needs in ... to develop new treatments for osteoarthritis. One such study ... osteoarthritis are being investigated, and early trials of stem-cell ...
(Date:5/25/2016)... , May 25,2016 FDA ... near-infrared Cellvizio platform for urological and surgical applications ... MKEAY) inventor of Cellvizio®, the multidisciplinary confocal laser ... milestone in the US with the 12 th ... Drug Administration (FDA). This new FDA clearance covers ...
Breaking Medicine Technology: